Quell Therapeutics
Development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system.
Quell Therapeutics has raised €138M across 1 funding round from 10 investors, most recently a Series B round in Nov 2021. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKwww.quell-tx.com ↗
Total raised
€138M
€138,346,932
Funding rounds
1
Investors
10
distinct backers
Active since
2021-11
latest 2021-11
Funding by year
EUR raised per yearQuell Therapeutics — funding by year — interactive chart.
Data table
| Quell Therapeutics — funding by year | |
|---|---|
| 2021 | €138M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-11-29 | Series B | €138M | British Patient Capital,Fidelity Management & Research Company LLC,Janus Henderson Investors,Jeito Capital,Monashee Investment Management LLC,Point72 Ventures+4 more | View deal → |
Investors
10Related news
- Quell Therapeutics Raises $156M in Series B Financingfinsmes.com · 2021-11
Similar companies
same sector or countryGlobal coverage: FundingData